ライフサイエンスコーパス: Parkinson

1 Parkinson disease (PD) is a devastating, largely nonfami

2 Parkinson disease (PD), the most common movement disorde

3 Parkinson disease is a heterogeneous disease with rapidl

4 Parkinson disease is characterized by motor and nonmotor

5 Parkinson's disease (PD) affects millions of patients wo

6 Parkinson's disease (PD) is a common neurodegenerative d

7 Parkinson's disease (PD) is a multifactorial malady and

8 Parkinson's disease (PD) is a progressive neurodegenerat

9 Parkinson's disease (PD) is characterized by dopaminergi

10 Parkinson's disease (PD) pathogenesis may involve the ep

11 Parkinson's disease is a synucleinopathy that is charact

12 Parkinson's disease is caused by a loss of dopaminergic

13 Parkinson's disease is characterized by the presence of

14 Parkinson's disease is the second most common neurodegen

15 Parkinson's disease protein 7 (PARK7/DJ-1) was successfu

16 probable dementia with Lewy bodies (n = 1), Parkinson disease with mild cognitive impairment (n = 2)

17 We studied 22 individuals [8 Stroke and 14 Parkinson Disease (PD) subjects aged between 41 and 75 y

18 es and 180 355 controls), we identified 1691 Parkinson's disease cases, 81 Lewy body dementia cases,

19 The second cohort included 28 Parkinson's disease and 43 control samples.

20 cohort of patients with early MSA (n = 38), Parkinson disease (PD, n = 16), and dementia with Lewy b

21 ls (22 757 Parkinson's disease cases, 13 431 Parkinson's disease proxy cases, 622 Lewy body dementia

22 asets, totalling 217 165 individuals (22 757 Parkinson's disease cases, 13 431 Parkinson's disease pr

23 k factor for neurologic disorders, such as a Parkinson's disease-like syndrome known as manganism.

24 rative disorders (ND) like Alzheimer's (AD), Parkinson's (PD), Huntington's or Prion diseases share s

25 nts with de novo Parkinson disease, advanced Parkinson disease, and healthy control participants.

26 ; 19 men), and 31 participants with advanced Parkinson disease (60 years +/- 9; 16 women).

27 Patients with advanced Parkinson's can be treated by deep brain stimulation (DB

28 mortem studies on two patients with advanced Parkinson's disease 8 and10 years following AAV2-neurtur

29 tion of microglial activation with advancing Parkinson's disease, we investigated whether CSF and/or

30 xposure to lipid-lowering drugs might affect Parkinson's disease (PD) risk.

31 utilized to protect dopamine neurons against Parkinson's disease pathology.

32 Although Parkinson's disease commonly manifests with motor sympto

33 alleles that have been identified, although Parkinson's disease risk variants appear to be in close

34 alcohol-use disorder (34%, P = 0.00084) and Parkinson disease (34%, P = 0.0032) than in their corres

35 y or corticobasal syndrome (AUC=88.47%), and Parkinson's disease or multiple systems atrophy (AUC=81.

36 neuron-specific protein PGP9.5 (PGP9.5) and Parkinson disease 5 (PARK5), a DUB active in neurons tha

37 n the brains of Alzheimer's disease (AD) and Parkinson's disease (PD) with dementia (PDD) patients, w

38 urological disorders, including dementia and Parkinson's disease.

39 is, mild cognitive impairment, dementia, and Parkinson's disease, supporting the relevance of brainst

40 tric disorders, such as major depression and Parkinson's disease is enabled.

41 n underlie conditions such as depression and Parkinson's disease.

42 e between idiopathic Parkinson's disease and Parkinson's disease linked to heterozygous PRKN/PINK1 mu

43 ted with dementia with Lewy bodies (DLB) and Parkinson's disease (PD).

44 iation between mitochondrial dysfunction and Parkinson's disease (PD).

45 ssociation between the use of glitazones and Parkinson's disease [incidence rate ratio (IRR) 1.17; 95

46 DDRs are upregulated in Alzheimer's and Parkinson's disease (PD), and DDRs knockdown reduces neu

47 ological disorders including Alzheimer's and Parkinson's diseases.

48 ronal function and health in Alzheimer's and Parkinson's diseases.

49 on, have also been linked to Alzheimer's and Parkinson's diseases.

50 cal diseases, such as multiple sclerosis and Parkinson's disease.

51 ral sclerosis (ALS), multiple sclerosis, and Parkinson's disease, peripheral nervous system (PNS) dis

52 f heterozygous mutations in PRKN or PINK1 as Parkinson's disease risk factor.

53 reward, and pathological conditions such as Parkinson's disease and addiction.

54 e associated with Lewy body diseases such as Parkinson's disease and Lewy body dementia.

55 ifferences between synucleinopathies such as Parkinson's disease and multiple system atrophy have bee

56 eature of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and multiple sc

57 f treatments for related conditions, such as Parkinson's disease, for the management of common sympto

58 trigger a series of human diseases, such as Parkinson's disease, multifactor disorder and Type-II di

59 d Yahr scale, Montreal Cognitive Assessment, Parkinson's Disease Questionnaire-39 and PD subtype asse

60 a dual pharmacological action of attenuating Parkinson's disease (PD) motor symptoms and development

61 An epidemiological connection exists between Parkinson's disease (PD) and melanoma.

62 ations in alpha-synuclein are linked to both Parkinson's disease and Lewy body dementia; in particula

63 10 (C10) were recently identified as causing Parkinson's disease and amyotrophic lateral sclerosis/fr

64 erformance (AUC=0.86) in separating clinical Parkinson's disease from controls across populations.

65 TREM2 differed between CSF biomarker-defined Parkinson's disease participant subgroups.

66 esent study profiled two EMVs from different Parkinson's disease (PD) tissue sources: (a) neural prog

67 d multiple protein ratios that differentiate Parkinson's disease from healthy controls and validated

68 such as in the case of Alzheimer's disease, Parkinson's disease and Huntington's disease.

69 e system atrophy (MSA), Parkinson's disease, Parkinson's disease with dementia and dementia with Lewy

70 human diseases, such as Alzheimer's disease, Parkinson's disease, and type 2 diabetes.

71 brain maladies such as Alzheimer's disease, Parkinson's disease, brain lymphomas, and other ailments

72 tween LNB and dementia, Alzheimer's disease, Parkinson's disease, motor neuron disease, epilepsy, and

73 term risks of dementia, Alzheimer's disease, Parkinson's disease, motor neuron diseases, epilepsy, or

74 ased risks of dementia, Alzheimer's disease, Parkinson's disease, motor neuron diseases, or epilepsy.

75 implicated in the neurodegenerative disorder Parkinson's disease (PD); however, it is unclear how mit

76 pid eye movement sleep behavioural disorder, Parkinson's disease, dementia with Lewy bodies, multiple

77 from three families with autosomal dominant Parkinson's disease.

78 192, 33.85%) than in the autosomal-dominant Parkinson's disease cohort (10 of 242, 4.13%) and the sE

79 outcomes of the PD MED and Levodopa in Early Parkinson's Disease (LEAP) studies.

80 ibrillar alpha-Syn polymorphs trigger either Parkinson's disease or multiple system atrophy hallmarks

81 to identify novel genes that cause familial Parkinson's disease.

82 e of late-onset, autosomal-dominant familial Parkinson's disease (PD).

83 s the most commonly mutated gene in familial Parkinson's disease(1) and is also linked to its idiopat

84 ) gene are the most common cause of familial Parkinson disease.

85 nase 2 (LRRK2) is a common cause of familial Parkinson's disease (PD).

86 RK2) are the most frequent cause of familial Parkinson's disease.

87 ary refers to 'Brain-first versus body-first Parkinson's disease: a multi-modal imaging case-control

88 ired, now that gene-targeting approaches for Parkinson's disease have reached the clinical trial stag

89 a surgical therapy with class 1 evidence for Parkinson's disease (PD).

90 isease, are a common genetic risk factor for Parkinson disease, although the penetrance is low.

91 been identified as a common risk factor for Parkinson's disease (PD).

92 avioural disorder (RBD) are risk factors for Parkinson's disease (PD).

93 stress disorder (PTSD) are risk factors for Parkinson's disease (PD).

94 Michael J Fox Foundation for Parkinson's Research.

95 evelopment of new therapeutic principles for Parkinson's disease.

96 kers may be associated with reduced risk for Parkinson disease (PD).

97 We show that the common genetic risk for Parkinson's disease (PD) is associated with dopaminergic

98 Current therapeutic strategies for Parkinson's disease (PD) aim to delay progression or rep

99 n enigmatic enzyme and a relevant target for Parkinson's disease (PD).

100 imipramine, could be potential therapies for Parkinson's disease.

101 mpairment) on the phenotype of LRRK2 and GBA Parkinson's disease (PD), and on the prevalence of prodr

102 re than 6 million individuals worldwide have Parkinson disease.

103 uring mutations in PRKN/PINK1 and idiopathic Parkinson's disease patients remain elusive.

104 potential to discriminate between idiopathic Parkinson's disease and Parkinson's disease linked to he

105 such association was observed for idiopathic Parkinson's disease patients.

106 markers of disease progression in idiopathic Parkinson's disease (iPD).

107 We also analyzed six cases of idiopathic Parkinson's disease (PD), one case of familial PD, and s

108 PRKN/PINK1 mutations compared to idiopathic Parkinson's disease, which is in line with previous find

109 The concept of 'idiopathic' Parkinson's disease (PD) as a single entity has been cha

110 mography (PET) imaging that is used to image Parkinson's disease, brain tumors, and focal hyperinsuli

111 In Parkinson's disease (PD), gamma oscillatory activity in

112 In Parkinson's disease (PD), pathologically high levels of

113 In Parkinson's disease and its models, abnormal rates and p

114 In Parkinson's disease, bradykinesia is characterized by sl

115 ain DA nuclei are differentially affected in Parkinson's disease.

116 a-synuclein, a protein known to aggregate in Parkinson's disease, dementia with Lewy bodies, and mult

117 m human studies on microbiome alterations in Parkinson's disease, Alzheimer's disease, amyotrophic la

118 DBS is a standard of care in Parkinson disease, essential tremor and dystonia, and is

119 identifies several novel protein changes in Parkinson's disease cerebrospinal fluid that may be expl

120 ological degeneration of neural circuitry in Parkinson's disease.

121 Visual hallucinations are common in Parkinson's disease and are associated with poorer progn

122 fied a subnetwork of reduced connectivity in Parkinson's disease hallucinations.

123 nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD) not only stimulates focal targe

124 ucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD) remains unclear.

125 transplantation can rescue motor defects in Parkinson's disease (PD) models, whether and how grafts

126 development of impulse control disorders in Parkinson's disease.

127 involvement of the PSAP saposin D domain in Parkinson's disease.

128 of mitochondrial complex III dysfunction in Parkinson's disease.

129 factor (GDNF), and produce potent effects in Parkinson's disease (PD) mouse models.

130 tiple brain disorders and injuries, e.g., in Parkinson's disease or traumatic brain injury (TBI), and

131 nges that accompany visual hallucinations in Parkinson's disease and the organizational and gene expr

132 of alpha-synuclein, a protein implicated in Parkinson's disease that predominately nucleates on memb

133 r control, as evidenced by its importance in Parkinson Disease and related disorders.

134 ogate immune biomarker of neuronal injury in Parkinson's disease.

135 n brain and drives symptom lateralization in Parkinson's disease (PD), but its molecular determinants

136 modulating the LTP-like plasticity of M1 in Parkinson's disease.

137 he potential of IL6 as progression marker in Parkinson's disease due to PRKN/PINK1 mutations; (iii) i

138 Alterations of the gut microbiome in Parkinson disease (PD) have been repeatedly demonstrated

139 reduction in monoamine neurotransmission in Parkinson's patients.

140 a treatment for non-motor symptoms (NMS) in Parkinson's disease (PD).

141 proteolytic truncations of alphasyn occur in Parkinson's disease, Lewy body dementia, and multiple sy

142 connectivity of the nigrostriatal pathway in Parkinson disease (PD).

143 They can be precipitated in Parkinson's disease (PD) by dopamine replacement therapy

144 s now known that the pathological process in Parkinson disease may begin decades before the clinical

145 re, we demonstrate that Netrin1 reduction in Parkinson's disease (PD) activates MST1, which selective

146 he demonstrated implication of the retina in Parkinson disease (PD) pathology and the importance of d

147 n vivo, consistent with a pathogenic role in Parkinson's disease.

148 ta activity is linked to symptom severity in Parkinson's disease (PD), but few studies have character

149 the substantia nigra pars compacta (SNpc) in Parkinson disease (PD) is not uniform, as dopamine neuro

150 cause of dopamine deficit in the striatum in Parkinson's disease.

151 m is one of most common nonmotor symptoms in Parkinson's disease (PD), but the molecular role of the

152 deep brain stimulation on motor symptoms in Parkinson's disease.

153 her levels of alpha-synuclein (alpha-syn) in Parkinson's disease patients.

154 tau in Alzheimer disease, alpha-synuclein in Parkinson disease, and TAR DNA-binding protein 43 in amy

155 ghlight the importance of genetic testing in Parkinson's disease patients with age at onset < 40 year

156 Data mining of the brain transcriptome in Parkinson disease patients supported CR4 as an active al

157 These include Parkinson's disease, ADHD, schizophrenia, and mood disor

158 ting neurodegenerative conditions, including Parkinson's disease (PD), dementia with Lewy bodies (DLB

159 ted in neurodegenerative diseases, including Parkinson's and amyotrophic lateral sclerosis.

160 ons in neurodegenerative diseases, including Parkinson's disease, Lewy body dementia, and multiple sy

161 ed neurological movement disorders including Parkinson's Disease (PD) and Essential Tremor (ET).

162 um of neurodegenerative disorders, including Parkinson's disease (PD).

163 many neurodegenerative disorders, including Parkinson's disease (PD).

164 different neurological disorders, including Parkinson's disease.

165 a wide range of synucleinopathies, including Parkinson's Disease.

166 genic/likely pathogenic variants in 23 known Parkinson's disease-associated genes occurred more frequ

167 likely pathogenic variants involved in known Parkinson's disease-associated genes.

168 nts appear to be in close proximity to known Parkinson's disease genes and lysosomal-related genes.

169 isease, and whether these overlap with known Parkinson's disease risk variants.

170 ogical material for addressing diseases like Parkinson's Disease and Epilepsy.

171 ase in the pathogenesis of PRKN/PINK1-linked Parkinson's disease.

172 a role for inflammation in PRKN/PINK1-linked Parkinson's disease.

173 ifferentiate, using a physiological measure, Parkinson's disease patients with impulse control disord

174 We also demonstrate that medicated Parkinson's disease patients exert similar effort to gai

175 which include multiple system atrophy (MSA), Parkinson's disease, Parkinson's disease with dementia a

176 Within this network, Parkinson's disease patients with hallucinations showed

177 11; 11 women), 29 participants with de novo Parkinson disease (64 years +/- 10; 19 men), and 31 part

178 d October 2015 for participants with de novo Parkinson disease, advanced Parkinson disease, and healt

179 ntion of diseases such as diabetes, obesity, Parkinson's, Alzheimer's, and others.

180 gh our understanding of the genetic basis of Parkinson's disease has advanced considerably, much rema

181 repeat kinase 2 (LRRK2) is a common cause of Parkinson's disease (PD) and results in age-related dopa

182 les, representing 40 patients) consisting of Parkinson's disease and healthy control samples from thr

183 potential to influence the disease course of Parkinson's disease, at least in this subset of patients

184 ia/macrophage derived exosomes in the CSF of Parkinson's disease patients, we confirmed the presence

185 electrochemical sensors for the detection of Parkinson's disease biomarkers.

186 trajectory and predictors for development of Parkinson's disease.

187 lation is associated with the development of Parkinson's Disease.

188 Diagnosis of Parkinson disease is based on history and examination.

189 and K(i) change found significant effects of Parkinson disease.

190 SNCA has been implicated in the etiology of Parkinson's disease (PD); however, the normal function o

191 st genetic and environmental risk factors of Parkinson's disease, whereas loss of ATP13A2 compromises

192 aSN) is an important histological feature of Parkinson disease.

193 m involvement precedes the motor features of Parkinson's disease (PD).

194 in one hemisphere improved motor features of Parkinson's disease in selected patients with asymmetric

195 of dopaminergic neurons in familial forms of Parkinson's disease but the precise pathogenic mechanism

196 we know relatively little of the genetics of Parkinson's disease in other populations.

197 ) accumulation is a pathological hallmark of Parkinson's disease.

198 ignificant enrichment of the heritability of Parkinson's disease within the substantia nigra module.

199 Compared with the incidence of Parkinson's disease in the comparison group (10 per 10 0

200 etic spectrum and clinical manifestations of Parkinson's disease in mainland China and expand the exi

201 bumin-expressing neurons in a mouse model of Parkinson's disease, we discovered evidence for an upreg

202 eficits of dopamine-depleted mouse models of Parkinson's disease, where cell type-specific optogeneti

203 n and are associated with the early onset of Parkinson Disease.

204 hibitors and GLP-1 mimetics and the onset of Parkinson's disease (IRR 0.64; 95% CI 0.43-0.88; P < 0.0

205 Specifically, the age at onset of Parkinson's disease patients with pathogenic/likely path

206 Palliative care is part of Parkinson disease management.

207 ual hit hypothesis about the pathogenesis of Parkinson disease (PD) suggests that the brainstem is a

208 ccepted as a key step in the pathogenesis of Parkinson's disease (PD).

209 osomes predates the clinical presentation of Parkinson's disease (PD), offering a means of developing

210 igra involved in the degeneration process of Parkinson disease.

211 changes that occur during the progression of Parkinson's disease pathology will aid the development o

212 ion neural circuit during the progression of Parkinson's disease.

213 current limitations and the broader range of Parkinson disease features that dopamine cell replacemen

214 mimetics is associated with a lower rate of Parkinson's disease compared to the use of other oral an

215 A recent study found a decreased risk of Parkinson disease (PD) associated with the beta2 adrener

216 served to be associated with a lower risk of Parkinson disease (PD) in previous epidemiologic studies

217 have examined the modulation of the risk of Parkinson's disease as a result of the use of beta-adren

218 indings suggest that the increase in risk of Parkinson's disease associated with beta-adrenoceptor an

219 We compared the risk of Parkinson's disease in patients with diabetes exposed to

220 Population data for risk of Parkinson's disease in users of the newer types of drugs

221 tidase 4 (DPP4) inhibitors, with the risk of Parkinson's disease of users of any other oral glucose l

222 by a dose-dependent decrease in the risk of Parkinson's disease with chronic beta-adrenoceptor agoni

223 beta-adrenoceptor antagonists on the risk of Parkinson's disease would be small compared with other P

224 have been shown to contribute to the risk of Parkinson's disease, and currently 90 independent risk v

225 agonist propranolol and an increased risk of Parkinson's disease, while the chronic use of the beta-a

226 hibitors that specifically target seeding of Parkinson's disease (PD)-associated alpha-synuclein (alp

227 xosomes as biomarkers across the spectrum of Parkinson's disease, multiple system atrophy and other p

228 The clinical spectrum of Parkinson's disease-associated gene carriers in this mai

229 locus in genome-wide association studies of Parkinson disease (PD).

230 effective therapy for the motor symptoms of Parkinson's disease (PD).

231 evice for the treatment of motor symptoms of Parkinson's disease.

232 peutic option for managing motor symptoms of Parkinson's disease.

233 alamic nucleus is a symptomatic treatment of Parkinson's disease but benefits only to a minority of p

234 By use of Parkinson's disease as a model condition, we show an int

235 se mutations cause, or increase the risk of, Parkinson's disease (PD) have been identified.

236 Research on Parkinson's disease most often focuses on the ability of

237 Previous studies on Parkinson's disease mechanisms have shown dysregulated e

238 RKN are the most common cause of early onset Parkinson's disease.

239 s in Parkin are a major cause of early-onset Parkinson's disease (PD).

240 ociated with autosomal recessive early-onset Parkinson's disease (PD).

241 arkinsonism with dementia(1)-and early-onset Parkinson's disease(2).

242 ed in individuals suffering from early-onset Parkinson's disease.

243 eimer's Disease, frontotemporal dementia, or Parkinson's Disease.

244 degenerative diseases such as Alzheimer's or Parkinson's are associated with the prion-like propagati

245 s disease would be small compared with other Parkinson's disease risk factors and would be similar to

246 (n = 102) and from a comparative population (Parkinson's disease or healthy participants, n = 61).

247 ynuclein and clusterin measurement predicted Parkinson's disease from other proteinopathies with AUC=

248 ained by reverse causation because prodromal Parkinson's disease is often associated with non-specifi

249 verity in patients with early or progressing Parkinson's disease and patients with idiopathic rapid e

250 sociation study and analysed the most recent Parkinson's disease-associated genetic risk score to det

251 d more frequently in the autosomal-recessive Parkinson's disease cohort (65 of 192, 33.85%) than in t

252 f CNS diseases including multiple sclerosis, Parkinson's disease and amyotrophic lateral sclerosis re

253 domain (rs4747203 and rs885828) in sporadic Parkinson's disease had significantly higher allele freq

254 rapeutic intervention.SIGNIFICANCE STATEMENT Parkinson's disease (PD) prevalence is projected to rise

255 ns such as Alzheimer's disease (AD), stroke, Parkinson's disease, Amyotrophic lateral sclerosis (ALS)

256 nverted haplotype of the MAPT (encoding tau) Parkinson's disease risk locus, identifying putative ect

257 ss influence over other brain regions), than Parkinson's disease patients without hallucinations and

258 Parkin has functions in the nucleus and that Parkinson's disease-associated Parkin mutants, ParkinR42

259 Here, we show that the Parkinson's disease (PD)-related kinase LRRK2 is activat

260 The PPIase CypA colocalizes with the Parkinson's disease (PD)-associated protein alpha-synucl

261 its interaction and colocalisation with the Parkinson's disease-associated E3 ubiquitin ligase Parki

262 Twenty-three Parkinson's disease patients with a history of impulse c

263 bilizes alpha-synuclein fibrils connected to Parkinson's disease.

264 dividuals with freezing of gait (FoG) due to Parkinson's disease (PD) have small and long anticipator

265 aired 5'-phosphatase activity, also leads to Parkinson's disease (PD)-like pathologies in mice.

266 aling of the VGLUT3-mGluR5 axis is linked to Parkinson disease, anxiety disorders, and drug addiction

267 uman alpha-synuclein (alphaSyn) is linked to Parkinson's disease (PD) pathology.

268 rstood factor in human conditions related to Parkinson's disease and complex behaviors.SIGNIFICANCE S

269 LRRK2 associates with the susceptibility to Parkinson's disease, Crohn's disease, and mycobacteria i

270 pamine neurons are especially susceptible to Parkinson's disease and prematurely degenerate in the co

271 r of neurons expressing dopamine could treat Parkinson's disease, or one affecting the number express

272 ent brain and is in clinical trials to treat Parkinson's disease patients.

273 ong been an attractive prospect for treating Parkinson disease.

274 d Montreal Cognitive Assessment, and Unified Parkinson's Disease Rating Scale score was obtained in p

275 ement Disorder Society [MDS]-revised Unified Parkinson Disease Rating Scale [UPDRS] [I-III] total sco

276 using the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

277 es on the Movement Disorders Society Unified Parkinson's Disease Rating Scale (total score 4.6 [SD 4.

278 ion of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS-III), and el

279 he primary outcome was change in the Unified Parkinson's Disease Rating Scale (UPDRS) parts I to III

280 D scored significantly higher on the Unified Parkinson's Disease Rating Scale motor subscale than oth

281 STN is modulated in a rhythmic pattern when Parkinson's patients perform stepping movements, raising

282 ynuclein aggregates that are associated with Parkinson's disease and multiple system atrophy correspo

283 A gene associated with Parkinson's disease regulates mitochondrial homeostasis,

284 brospinal fluid from patients diagnosed with Parkinson's disease and samples from patients with multi

285 alpha-synuclein remains stably elevated with Parkinson's disease progression.

286 derived cell transplants in individuals with Parkinson disease have been variable, in part owing to t

287 e wrist worn sensors in 35 participants with Parkinson's disease in-clinic and 25 participants monito

288 For all patients with Parkinson disease, treatment is symptomatic, focused on

289 in a naturalistic fashion, 55 patients with Parkinson's disease (19 females, mean age 62, mean Hoehn

290 regulated in the cerebellum of patients with Parkinson's disease (PD) and Essential Tremor (ET).

291 tivity in the basal ganglia of patients with Parkinson's disease (PD) are associated with impaired mo

292 arameters in a large cohort of patients with Parkinson's disease (PD) compared to controls using a fu

293 eanwhile, studies of memory in patients with Parkinson's disease have focused on overall memory capac

294 Patients with Parkinson's disease have reduced reward sensitivity rela

295 motor symptoms, a majority of patients with Parkinson's disease subsequently develop cognitive impai

296 Patients with Parkinson's disease who had 2 h or more of off time per

297 ly normal elderly subjects, 45 patients with Parkinson's disease with no cognitive impairment, 86 wit

298 res the LTP-like plasticity in patients with Parkinson's disease.

299 nd therapy for off episodes in patients with Parkinson's disease.

300 in PD.SIGNIFICANCE STATEMENT In persons with Parkinson's disease, gait dysfunction and the associated